Allergen-specific immunotherapy with recombinant allergens

Current Topics in Microbiology and Immunology

Volumn 352, Issue 1, 2011, Pages 43-54

  Pauli, G ^a   Malling, Hans Jørgen ^b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; BET V 1 FRAGMENT; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; NATURAL BET V 1; PLACEBO; RECOMBINANT ALLERGEN; RECOMBINANT BET V 1; RECOMBINANT BET V 1 TRIMER; RECOMBINANT BIRCH ALLERGEN; RECOMBINANT BIRCH ALLERGEN DERIVATIVE; RECOMBINANT GRASS ALLERGEN; UNCLASSIFIED DRUG; ALLERGEN; BET V 1A TRIMER; BIRCH POLLEN EXTRACT; PHL P 1; PHL P 2; PHL P 5A; PHL P 5B; PHL P 6; PURIFIED BET V 1; RBET V 1;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ALLERGIC URTICARIA; ANAPHYLAXIS; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; ASTHMA; CLINICAL EFFECTIVENESS; CYTOKINE PRODUCTION; DISEASE SEVERITY; DYSPNEA; GASTROINTESTINAL DISEASE; GRASS POLLEN; HUMAN; HYPOTENSION; IMMUNOREACTIVITY; IMMUNOTHERAPY; PHLEUM PRATENSE; PRIORITY JOURNAL; RHINOCONJUNCTIVITIS; SENSITIZATION; SUBCUTANEOUS IMMUNOTHERAPY; URTICARIA; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; B LYMPHOCYTE; BIRCH POLLEN INDUCED RHINITIS; DRUG EFFICACY; DRUG SAFETY; GENERALIZED URTICARIA; IMMUNOGENICITY; LOCAL URTCARIA; LOCAL URTICARIA; LOCAL UURTICARIA; OUTCOME ASSESSMENT; POLLEN ALLERGY; PREVENTION AND CONTROL; PROVOCATION TEST; RISK FACTOR; SCORING SYSTEM; SKIN SENSITIVITY; SKIN TEST; SYMPTOM; T LYMPHOCYTE; TREATMENT DURATION;

ANTIGENS, PLANT; ASTHMA; BETULA; CLINICAL TRIALS AS TOPIC; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNE TOLERANCE; PHLEUM; RECOMBINANT PROTEINS; RHINITIS, ALLERGIC, SEASONAL;

PHLEUM PRATENSE;

EID: 80053515411     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/82_2011_125     Document Type: Article

References (35)

1. Adkis CA, Adkis M (2009) Mechanisms and treatment of allergic disease in the big picture of regulatory T-cells. J Allergy Clin Immunol 123:735-746
2. Bousquet J, Malling HJ, Locket RF (1998) World Health Organization Position Paper. Allergen immunotherapy: therapeutical vaccines for allergic diseases. Allergy 53(Suppl 54):1-15
3. Briner TJ, Kuo M, Keating KM, Rodgers B, Greenstein J (1993) Peripheral T-cell tolerance induced in na and primed mice by sub-cutaneous injection of peptides from the major cat allergen Fel D 1. Proc Natl Acad Sci USA 90:7608-7616
4. Canonica GW, Baena-Cagnani, Bousquet J et al (2007) Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 62:317-324
5. Drew AC, Eusebius NP, Kenins L et al (2004) Hypoallergenic variants of the major latex allergen Hev b 6.01 retaining human T lymphocyte reactivity. J Immunol 173:5872-5889
6. Ferreira F, Ebner C, Kramer B et al (1998) Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy. FASEB J 12:231-242 (Pubitemid 28080193)
7. Ferreira F, Wallner M, Breiteneder H, Hartl A, Tahlmer J, Ebner C (2002) Genetic engineering of allergens: future therapeutic products. Int Arch Allergy Immunol 128:171-178 (Pubitemid 34765222)
8. Geibler W (2006) The European guidelines regulating allergen products and the Ph. Eur. Monograph on allergens: transformation into everyday practice. In: Kurth R, Haustein D (eds) Regulatory control and standardization of allergenic extracts. GIT Verlag, Darmstadt
9. Hirahara K, Tatsuta T, Takatori T, Ohtsuki M, Kirinaka H, Kawaguchi J et al (2001) Preclinical evaluation of an immunotherapeutic peptide comprising 7 T-cell determinants of Cry j 1 and Cry j 2, the major Japanese cedar pollen allergens. J Allergy Clin Immunol 108:94-100 (Pubitemid 32662238)
10. Holm J, Gajhede M, Ferreras M et al (2004) Allergy vaccine engineering: epitope modulation of recombinant Bet v 1 reduces IgE-binding but retains protein folding pattern for induction of protective blocking-antibody responses. J Immunol 173:5258-5267 (Pubitemid 39387809)
11. Hoyne GFR, O'Hehir DC, Wraith WR, Thomas WR, Lamb JR (1993) Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in na and sensitized mice. J Exp Med 178:1783-1788 (Pubitemid 23318458)
12. James LK, Durham SR (2008) Update on mechanisms of allergen injection immunotherapy. Clin Exp Allergy 38:1074-1088
13. Juniper EF, Guyatt GH (1991) Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 21:77-83
14. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O (2005) Allergen specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 116:608-613 (Pubitemid 41267135)
15. Klimek L, Bachert C, Doemer C, Meyer H, Narkus A (2005) Specific immunotherapy with recombinant birch pollen allergen rBet v 1-FV is clinically efficacious. Allergy Clin Immunol Int (Suppl N1):15
16. Malling HJ (1998) Immunotherapy as an effective tool in allergy treatment. Allergy 53:461-472
17. Mazaruela EG, Rodriguez R, Barber D, Villalba M, Batanero E (2006) Hypoallergenic mutants of Ole e 1, the major olive pollen allergen, as candidates for allergy vaccines. Clin Exp Allergy 37:251-260
18. Niederberger V, Pauli G Grönlund et al. (1998) Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera from different populations. J Allergy Clin Immunol 102:579-591
19. Norman PS, Ohman JL Jr, Long AA et al (1996) Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 154:1623-1628 (Pubitemid 26424925)
20. Oldfield WL, Larche M, Kay AB (2002) Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomized controlled trial. Lancet 360:47-53 (Pubitemid 34756492)
21. Orlandi A, Grasso F, Corinti S et al (2004) The recombinant major allergen of Parietaria judaica and its hypoallergenic variant: in vivo evaluation in a murine model of allergic sensitization. Clin Exp Allergy 34:470-477 (Pubitemid 38373012)
22. Pauli G, Purohit A, Oster JP et al (2000) Comparison of genetically engineered hypoallergenic rBet v1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population. Clin Exp Allergy 30:1076-1084 (Pubitemid 30619760)
23. Pauli G, Larsen TH, Rak S et al (2008) Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 122:951-960
24. Pfleiderer M (2006) Marketing authorization for recombinant products in Europe. In: Löwer J, Vieths S (eds) Regulatory control and standardization of allergenic extracts. Verlag Chmielorz
25. Wiesbaden Purohit A, Niederberger V, Kronqvist M et al (2008) Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy 38:1514-1525
26. Swoboda I, de Weerd N, Bhalla PL et al (2002) Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE binding capacity: candidates for grass pollen-specific immuno-therapy. Eur J Biochem 32:295-302
27. Takai T, Yokota T, Yasue N et al (1997) Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy. Nat Biotechnol 15:754-758
28. Valenta R, Niederberger V (2007) Recombinant allergens for immunotherapy. J Allergy Clin immunol 119:826-830 (Pubitemid 46527833)
29. Valenta R, Duchene M, Vrtala S et al (1991) Recombinant allergens for immunoblot diagnosis of tree-pollen allergy. J Allergy Clin Immunol 88:889-894
30. Valenta R, Vrtala S, Ebner C et al (1992) Diagnosis of grass pollen allergy with recombinant timothy grass (Phleum pratense) pollen allergens. Int Arch Allergy Immunol 97:287-294
31. Van Hage-Hamsten M, Kronqvist M, Zetterstrom O et al (1999) Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season. J Allergy Clin Immunol 104:969-977 (Pubitemid 29532117)
32. Van Hage-Hamsten M, Johansson E, Roquet A et al (2002) Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild-type in patients with allergic rhinitis. Clin Exp allergy 32:1448-1453 (Pubitemid 35278912)
33. van Ree R, Chapman MD, Ferreira F, Vieths S, Bryan D et al (2008) The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy 63:310-326 (Pubitemid 351224688)
34. Vrtala S (2008) From allergen genes to new forms of allergy diagnosis and treatment. Allergy 63:299-309 (Pubitemid 351224687)
35. Vrtala S, Focke-Tejkl M, Swoboda I, Kraft D, Valenta R (2004) Strategies for converting allergens into hypoallergenic vaccine candidates. Methods 32:313-320 (Pubitemid 38201285)